MedPath

Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

Not Applicable
Recruiting
Conditions
Dexmedetomidine
Interventions
Drug: Dexmedetomidine with Mannitol
Registration Number
NCT07064720
Lead Sponsor
Cairo University
Brief Summary

Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria

ASA I-II Patients scheduled for elective robot-assisted laparoscopic prostatectomy

Exclusion Criteria
  • • ASA physical status > II

    • Cardiac patients
    • Cerebrovascular disease
    • Glaucoma
    • Hepatic failure
    • Renal failure
    • History of anaphylactic reaction to dexmedetomidine or mannitol
    • Hemodynamic instability
    • Cannot measure ONSD for example due to ophthalmological problems.
    • Any cause of preoperative increase in ICP for example intracranial space occupying lesions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group (D)Dexmedetomidine with MannitolDexmedetomidine with Mannitol
Group (M)Mannitol (20%)Mannitol only
Primary Outcome Measures
NameTimeMethod
optic nerve sheath diameter90 minutes
Secondary Outcome Measures
NameTimeMethod
Postoperative cardiac complications24 hours
Postoperative neurologic complications24 HOURS
Duration of hospital stay30 days

Trial Locations

Locations (1)

facility of medicine Cairo university

🇪🇬

Cairo, Egypt

facility of medicine Cairo university
🇪🇬Cairo, Egypt
Amr Wahdan
Contact
01001422499
amrwahdan@kasraliny.edu.eg
Heba Ismail
Contact
01220807670
Samar Hassan Koshek
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.